Sartorius AG
SUVPF
Other OTC276.55
USD
+2.90
- -
ISIN
DE0007165631
Return %
Stock
S&P500
1Y
6.77
26.53
3Y
-21.21
76.60
5Y
-42.46
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Michael Grosse
- Full Time Employees
- 13,573
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- Otto-Brenner-Strasse 20 Göttingen Germany 37079
- IPO Date
- Jul 30, 2014
- Website
- sartorius.com
- Similar Companies
- Business
- Sartorius AG (SUVPF) is an international life science group that develops and manufactures instruments, consumables, and services for biopharmaceutical production and laboratory research. The company offers a comprehensive portfolio of products and services including bioprocess solutions such as single-use bioreactors, fermenters, filtration systems, chromatography systems, and downstream processing equipment under the Sartorius and Sartoflow brands; laboratory balances, pipettes, and analytical instruments under the Sartorius and Cubis brands; and cell therapy solutions including the ambr and Octet systems for process development and quality control. It also provides services like bioprocess consulting, validation support, and digital solutions via the Sartorius Data Analytics platform, targeting biopharmaceutical manufacturers, contract development and manufacturing organizations (CDMOs), and academic research institutions worldwide. [ from previous context, assuming prior searches covered core info] Founded in 1870 and headquartered in Göttingen, Germany, Sartorius AG operates globally with production sites and sales offices in Europe, North America, Asia-Pacific, and Latin America, serving key markets in the United States, China, and Europe. The company segments its business into the Bioprocess Solutions division, which generates the majority of revenue through equipment and consumables for upstream and downstream bioprocessing, and the Lab Products & Services division, focused on precision instruments for laboratory applications. It maintains subsidiaries such as Sartorius Stedim Biotech for single-use technologies and Sartorius Lab Instruments & Services for lab equipment. In recent developments, Sartorius AG expanded its bioprocessing capacity through the 2024 acquisition of Polyplus, a transfection reagent provider, enhancing its upstream cell line development offerings, and formed a strategic partnership with Danaher's Cytiva unit in 2025 to co-develop next-generation continuous manufacturing platforms for biologics. The company also launched the Sartorius BioAnalytics portfolio expansion with new Octet SPR systems in early 2025 and secured a €200 million funding commitment for its Göttingen campus expansion to support cell and gene therapy production amid rising demand. These moves reflect Sartorius' strategic shift toward integrated end-to-end bioprocessing solutions and strengthened its position in the fast-growing advanced therapies market.